8:00 am Online Registration & Virtual Coffee Networking

8:45 am Chair’s Opening Remarks

9:00 am Opening Keynote: Unity Biotechnologies’ Pipeline Progression: From Mouse Models to First-in-Human Trials

Synopsis

  • Examine the role of senescent cells in diseases of aging and the promise of transformative medicines
  • Explore discovery and development of senolytic agents, a new class of therapeutics
  • Targeting senescence biology in first-in-human trials in diabetic retinopathies
  • Understand the potential impact of targeting senescence and related biologies of aging in diseases of the eye, brain and beyond

9:30 am Practical Drug Development for the Field of Aging Biology

Synopsis

  • Examine how improved health span is a challenging clinical endpoint
  • Explore how preventive therapies of any sort must have a high bar for safety
  • Leverage effective strategies for stepwise de-risking/confidence
    building and understand how they are necessary

10:00 am Using Neuroimaging to Inform Drug Development Throughout the Pathologic Trajectory

  • David Scott Vice President Neuroscience & Scientific Director , Bioclinica

Synopsis

  • Highlight medical imaging techniques for CNS drug development
  • Examine why imaging biomarkers provide insight into drug mechanism by informing target engagement and pharmacologic activation
  • Explore how these markers will also be crucial for prevention trials, where interventions may occur decades in advance of any clinical symptom
  • Understand how these advanced imaging techniques can be deployed in the clinical trial space

10:20 am When Does Aging Begin?

  • Ronald Kohanski Director, Division of Aging Biology, National Institute on Aging (NIH)

Synopsis

  • Explore when aging actually begins and why the answer might be useful
  • If aging is systems failures (declines), are these failures the same across the life course?
  • How might we learn experimentally when aging begins?

10:50 am Morning Break & Virtual Speed Networking

11:35 am A Fresh Take on an Old Classic: Therapeutically Modulating IGF Signaling through PAPP-A Inhibition

Synopsis

  • Explore how inhibition of insulin/IGF signaling is the most validated antiaging intervention known
  • Examine PAPP-A: An extracellular IGFBP protease that increases local IGF bioavailability, extends lifespan and health span when deleted, and avoids endocrine compensation, making it a compelling target for IGF pathway modulation
  • Review Calico Lab’s PAPP-A neutralizing antibody; explaining how reduced IGF signaling extends health span and lifespan due to characterizing its effects in-vivo and identifying clear biological activity and novel mechanisms of action
  • Discuss how PAPP-A inhibition may be a safe and effective therapeutic strategy for reducing IGF signalling

12:05 pm An Aging Intervention that Increases Lifespan & Compresses Morbidity

  • Gordon Lithgow Professor & Vice President, Academic Affairs, Buck Institute on Aging

Synopsis

  • Is it trivial to find small molecule interventions in aging (in simple laboratory animals)?
  • Explore how health span increase is also attainable
  • Examine how extension of mouse lifespan and health span has been demonstrated

12:35 pm Aged B6 Mice: A Novel Model for Studying Human NASH

Synopsis

  • Explore how aged mice represent a new dietary model for NASH that accounts for the known risk factor of age in the human disease
  • Examine severe NASH phenotypes and how they are are observed in aged mice when placed on a diet high in fat, fructose and cholesterol
  • Understand how both male and female aged mice are susceptible to the diet-induced NASH in aged model

1:05 pm Lunch & Virtual Networking

2:05 pm Therapeutics for Aging from the Plasma Proteome

Synopsis

  • Discuss how comprehensive profiling demonstrates significant changes of the plasma proteome over aging
  • Examine how reversal of multiple mechanisms relevant for the biology of aging can be achieved through plasma-based approaches
  • Explore how plasma fractions have been developed with efficacy in mouse models and clinical studies
  • Analyze how targeting individual key plasma proteins has preclinical and clinical impact

2:35 pm Rejuvenation Biotechnology: How Can the PhDs Help the MDs & the MBAs?

  • Aubrey de Grey Founder & Chief Scientific Officer, SENS Research Foundation

Synopsis

  • Discover how one by one, anti-aging damage repair therapies are moving into (expensive) clinical trials
  • Most clinical trials fail: Discuss how the rejuvenation biotechnology sector will be no different
  • Why do investors often oversimplify and lose nerve? Could this badly delay availability of powerful therapies?
  • Examine why researchers have huge influence over general-audience sentiment and why they must have the courage to use it

3:05 pm Mitochondrial Targeted Therapies & Longevity

Synopsis

  • Examine mitochondrial dysfunction and the aging process
  • Explore how mitochondrial-targeted therapeutics can slow, and even reverse age-related decline in animals
  • Discuss how mitochondrial-targeted therapeutics can do the same in humans
  • Consider and evaluate lifespan as a final frontier

3:35 pm Afternoon Break & Virtual Speed Networking

4:20 pm The Interplay of Aging & Fibrosis: AI-Powered Target Discovery & Validation of Novel Pan-Fibrotic Protein Targets

Synopsis

  • Discuss senofibrosis and fibrosenescenc: The role of fibrosis in aging
  • Examine the discovery of novel targets in fibrosis
  • Explore generation of novel molecules for pan-fibrotic targets
  • Analyze in-vivo and in-vitro validation of novel pan-fibrotics

4:50 pm Panel Discussion: A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities

Synopsis

  • Examining what we do and do not know about the aging process
  • Exploring the targeting of aging as a disease vs. aging as a common factor for different conditions
  • Analyzing the current R&D landscape for anti-aging therapeutics
  • Discussing recent breakthroughs and the growing interest in this space – attracting funding/ partnerships, important learnings to date and perspectives on future directions

5:50 pm Chair’s Closing Remarks

6:00 pm End of Day 1